CoChat
Sign Up
Cited by 40Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management

Open access
Kenney, Shannon R., Anderson, Bradley J., Bailey, Genie L., Stein, Michael D.·2018·Journal of Substance Abuse Treatment
DOI 10.1016/j.jsat.2018.08.011PMC PMC6152924
Open this paper in CoChat — free account

Abstract

Background In the current study, we examined factors predicting willingness to receive buprenorphine treatment and preferences for various buprenorphine formulations (oral, injection, implant) among persons in opioid withdrawal management. Methods Participants were three hundred thirty-eight persons entering brief inpatient opioid withdrawal management programs at two sites. We used t-tests and Pearson χ2 - tests of independence to compare participants willing and unwilling to be prescribed buprenorphine in the future. Among persons willing to receive buprenorphine, we used multinomial logistic regression to estimate the adjusted effects of potential correlates of type of buprenorphine formulation preferred. Results Participants averaged 33.9 (±9.5) years of age, 70.4% were male, 82.8% were White, and 11.0% were Latino/a. In all, 55.6% of participants had been prescribed buprenorphine in the past, and 54.7% were willing to use prescribed buprenorphine in the future. Those reporting past month illicit buprenorphine use and prior overdose were more willing to use prescribed buprenorphine. Of these (n = 180), most preferred daily buprenorphine formulations (tablet or film) (48.6%) over a weekly or monthly injection (23.1%) or bi-annual implant (28.3%). Conclusions Past buprenorphine prescription does not predict future willingness to restart. Among those willing to use buprenorphine, newer formulations of buprenorphine appealed to more than half of the participants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jsat.2018.08.011

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Almost a quarter of respondents preferred extended-release buprenorphine when given a choice between transmucosal buprenorphine, extended-release buprenorphine, or a buprenorphine implant.

    “a study showed that almost a quarter of respondents preferred extended-release buprenorphine when given a choice between transmucosal buprenorphine, extended-release buprenorphine, or a buprenorphine implant.41”

    From Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder (2023) · cites this paper as [41]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. Ahamad, 2015, Factors associated with willingness to take extended release naltrexone among injection drug users, Addiction Science & Clinical Practice, 10, 10.1186/s13722-015-0034-5 · DOI
  2. Alho, 2007, Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users, Drug and Alcohol Dependence, 88, 75, 10.1016/j.drugalcdep.2006.09.012 · DOI
  3. Awgu, 2010, Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance, Journal of Psychoactive Drugs, 42, 339, 10.1080/02791072.2010.10400696 · DOI
  4. Bailey, 2013, Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification, Journal of Substance Abuse Treatment, 45, 302, 10.1016/j.jsat.2013.04.002 · DOI
  5. Bell, 2009, Comparing overdose mortality associated with methadone and buprenorphine treatment, Drug and Alcohol Dependence, 104, 73, 10.1016/j.drugalcdep.2009.03.020 · DOI
  6. Bell, 2009, Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment, Addiction, 104, 1193, 10.1111/j.1360-0443.2009.02627.x · DOI
  7. Connery, 2015, Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions, Harvard Review of Psychiatry, 23, 63, 10.1097/HRP.0000000000000075 · DOI
  8. Cunningham, 2013, Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes, Journal of Addiction Medicine, 7, 287, 10.1097/ADM.0b013e31829727b2 · DOI
  9. Fareed, 2014, Factors affecting noncompliance with buprenorphine maintenance treatment, Journal of Addiction Medicine, 8, 345, 10.1097/ADM.0000000000000057 · DOI
  10. Gossop, 2002, Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: Protective effect of coping responses, Addiction, 97, 1259, 10.1046/j.1360-0443.2002.00227.x · DOI
  11. Gowing, 2009, Buprenorphine for the management of opioid withdrawal, Cochrane Database of Systematic Reviews, 3, CD002025
  12. Hser, 2004, Relationship between drug treatment services, retention, and outcomes, Psychiatric Services, 55, 767, 10.1176/appi.ps.55.7.767 · DOI · Paper page
  13. Johanson, 2012, Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians, Drug and Alcohol Dependence, 120, 190, 10.1016/j.drugalcdep.2011.07.019 · DOI
  14. Johnson, 2003, Buprenorphine: How to use it right, Drug and Alcohol Dependence, 70, S59, 10.1016/S0376-8716(03)00060-7 · DOI
  15. Joosten, 2008, Effect of shared decision-making on therapeutic alliance in addiction health care, Patient Preference and Adherence, 2, 277, 10.2147/PPA.S4149 · DOI
  16. Joosten, 2008, Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status, Psychotherapy and Psychosomatics, 77, 219, 10.1159/000126073 · DOI · Paper page
  17. Ling, 2010, Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial, JAMA, 304, 1576, 10.1001/jama.2010.1427 · DOI
  18. Moratti, 2010, Intravenous misuse of buprenorphine: Characteristics and extent among patients undergoing drug maintenance therapy, Clinical Drug Investigation, 30, 3, 10.2165/11536020-000000000-00000 · DOI
  19. Pinto, 2010, The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment, Journal of Substance Abuse Treatment, 39, 340, 10.1016/j.jsat.2010.07.009 · DOI
  20. Ridge, 2009, Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence, Journal of Substance Abuse Treatment, 37, 95, 10.1016/j.jsat.2008.09.007 · DOI
  21. Rosenthal, 2013, Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine/naloxone, Addiction, 108, 2141, 10.1111/add.12315 · DOI
  22. Stein, 2012, The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine and methadone, Drug and Alcohol Dependence, 123, 72, 10.1016/j.drugalcdep.2011.10.016 · DOI
  23. Strain, 2011, Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films, Clinical Pharmacology and Therapeutics, 89, 443, 10.1038/clpt.2010.352 · DOI
  24. Tkacz, 2012, Compliance with buprenorphine medication-assisted treatment and relapse to opioid use, The American Journal on Addictions, 21, 55, 10.1111/j.1521-0391.2011.00186.x · DOI
  25. Uebelacker, 2016, Patients' beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification, Journal of Substance Abuse Treatment, 66, 48, 10.1016/j.jsat.2016.02.009 · DOI
  26. Volkow, 2014, Medication-assisted therapies—Tackling the opioid-overdose epidemic, The New England Journal of Medicine, 370, 2063, 10.1056/NEJMp1402780 · DOI
  27. White, 2009, Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence, Drug and Alcohol Dependence, 103, 37, 10.1016/j.drugalcdep.2009.03.008 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kenney, S. R., Anderson, B. J., Bailey, G. L., & Stein, M. D.
Affiliations
  • Brown University (US)
  • Butler Hospital (US)
  • Boston University (US)
Corresponding author
Kenney, Shannon R.
ORCID
Venue
Journal of Substance Abuse Treatment
Publisher
Elsevier BV
Published
2018-11
Volume
94
Pages
55-59
ISSN
0740-5472 (ISSN-L)
DOI
10.1016/j.jsat.2018.08.011
PMC
PMC6152924
OpenAlex
W2889481557
Cited by
40
References
1
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 9 · 2019: 5
FWCI
4.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Substance Abuse Treatment (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Alcohol Abuse and Alcoholism (R01AA020509)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
buprenorphine, opioid withdrawal, treatment preferences, opioid use disorder
MeSH terms
Administration, Oral, Adult, Buprenorphine, Drug Administration Schedule, Drug Implants, Female, Humans, Injections, Male, Narcotic Antagonists, Opioid-Related Disorders, Substance Withdrawal Syndrome, Tablets, Logistic Models, Young Adult, Patient Preference, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review